FdaApplication
BLA 125832
Identifiers
- fda_app_no: BLA125832
Properties
| Property | Value |
|---|---|
| applicant_name | Precigen, Inc. |
| application_type | BLA |
| approval_date | 2025-08-14 |
Revenue by product
PAPZIMEOS
| Period | Revenue |
|---|---|
| Q2 2026 | $53.1M |
| Q1 2026 | $21.6M |
| Q2 2025 | $0.0M |
| Q1 2025 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| PAPZIMEOS | — | 5x10^11PARTICLE UNITS | For Injection |
1 product